TD Asset Management Inc Sells 230,050 Shares of Pfizer Inc. $PFE

TD Asset Management Inc lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,927,083 shares of the biopharmaceutical company’s stock after selling 230,050 shares during the quarter. TD Asset Management Inc’s holdings in Pfizer were worth $94,564,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of PFE. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the fourth quarter worth $26,000. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at $26,000. HFM Investment Advisors LLC grew its holdings in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Evolution Wealth Management Inc. grew its holdings in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the last quarter. Finally, Abound Financial LLC acquired a new stake in shares of Pfizer during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on PFE shares. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $32.00 to $28.00 in a report on Monday, July 6th. Guggenheim reduced their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Bank of America decreased their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Pfizer in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Trading Up 1.6%

Shares of NYSE PFE opened at $27.30 on Wednesday. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a market cap of $155.57 billion, a PE ratio of 35.91 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average of $25.18 and a two-hundred day moving average of $26.21.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.3%. Pfizer’s dividend payout ratio is currently 226.32%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: EMA validates Lyme vaccine filing: The European Medicines Agency validated Pfizer and Valneva’s marketing application for their Lyme disease vaccine candidate, allowing the application to proceed to a full regulatory review. The filing follows late-stage data showing encouraging efficacy and safety. Approval could create a new commercial opportunity for Pfizer, although regulatory and launch risks remain. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Pipeline and intellectual-property support: Pfizer completed a Phase 1 study of its early-stage obesity candidate PF-08653944, maintaining optionality in a high-growth therapeutic market. A separate patent analysis also identified Pfizer as a leading holder of next-generation antibody-drug-conjugate patents, strengthening the company’s potential position in cancer treatment. Both developments are longer-term catalysts rather than immediate revenue drivers. Pfizer Advances Early Obesity Drug PF-08653944
• Neutral Sentiment: Healthcare-sector momentum: Healthcare indexes rose broadly late Tuesday, providing a favorable trading backdrop for defensive, dividend-paying pharmaceutical companies such as Pfizer. The sector move appears to be a market-wide factor rather than a Pfizer-specific fundamental change. Healthcare Stocks Climb Late Afternoon
• Neutral Sentiment: Obesity-drug competition and deal interest: Kailera Therapeutics’ large obesity-drug IPO highlights intense industry interest in the market and could increase attention on Pfizer’s pipeline or potential acquisition opportunities. At the same time, rising competition makes Pfizer’s early-stage program more speculative. Kailera Therapeutics Obesity IPO
• Negative Sentiment: Patent-cliff concerns remain: Despite Pfizer’s low valuation and attractive dividend, analysts continue to warn that upcoming patent expirations could pressure revenue and earnings as key products face generic or biosimilar competition. This remains the primary fundamental overhang on PFE. Pfizer Still Cheap Valuation Meets a Looming Patent Cliff

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.